Which has higher earnings & valuation, PRTC or OXB?

PureTech Health has higher earnings, but lower revenue than Oxford Biomedica. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health £6.37M 42.76 -£91.86M N/A N/A Oxford Biomedica £175.36M 3.60 -£143.51M -£31.96 N/A

Does the media favor PRTC or OXB?

In the previous week, PureTech Health had 2 more articles in the media than Oxford Biomedica. MarketBeat recorded 3 mentions for PureTech Health and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.00 beat PureTech Health's score of -0.12 indicating that Oxford Biomedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Oxford Biomedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PRTC or SLN?

PureTech Health presently has a consensus target price of GBX 508, suggesting a potential upside of 357.66%. Given PureTech Health's stronger consensus rating and higher probable upside, equities research analysts plainly believe PureTech Health is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, PRTC or SLN?

Silence Therapeutics has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health £6.37M 42.76 -£91.86M N/A N/A Silence Therapeutics £11.35M 0.00 N/A -£48.60 N/A

Do analysts rate PRTC or HZD?

PureTech Health currently has a consensus price target of GBX 508, suggesting a potential upside of 357.66%. Given PureTech Health's stronger consensus rating and higher possible upside, equities analysts clearly believe PureTech Health is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, PRTC or HZD?

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health £6.37M 42.76 -£91.86M N/A N/A Horizon Discovery Group plc (HZD.L) £54.63M 0.00 N/A -£5.50 N/A

Which has stronger earnings & valuation, AVCT or PRTC?

Avacta Group has higher earnings, but lower revenue than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avacta Group £113K 2,648.76 -£30.08M -£9.24 N/A PureTech Health £6.37M 42.76 -£91.86M N/A N/A

Does the media refer more to AVCT or PRTC?

In the previous week, Avacta Group had 1 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Avacta Group and 3 mentions for PureTech Health. Avacta Group's average media sentiment score of 0.00 beat PureTech Health's score of -0.12 indicating that Avacta Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate PRTC or ARIX?

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 357.66%. Given PureTech Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe PureTech Health is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, PRTC or ARIX?

Arix Bioscience has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health £6.37M 42.76 -£91.86M N/A N/A Arix Bioscience £14.16M 0.00 £14.96M £0.11 N/A

PureTech Health (PRTC) Competitors

GBX 112 +1.00 (+0.90%)

As of 11:04 AM Eastern

Compare

PRTC vs. OXB, SLN, HZD, AVCT, and ARIX

Should you buy PureTech Health stock or one of its competitors? PureTech Health's main competitors and comparable companies include Oxford Biomedica (OXB), Silence Therapeutics (SLN), Horizon Discovery Group plc (HZD.L) (HZD), Avacta Group (AVCT), and Arix Bioscience (ARIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PureTech Health compare to Oxford Biomedica?

PureTech Health (LON:PRTC) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

PureTech Health currently has a consensus price target of GBX 508, suggesting a potential upside of 357.66%. Oxford Biomedica has a consensus price target of GBX 613.32, suggesting a potential upside of 17.72%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

31.0% of PureTech Health shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 13.3% of PureTech Health shares are held by insiders. Comparatively, 25.8% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PureTech Health has higher earnings, but lower revenue than Oxford Biomedica.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£6.37M	42.76	-£91.86M	N/A	N/A
Oxford Biomedica	£175.36M	3.60	-£143.51M	-£31.96	N/A

PureTech Health has a net margin of 7.53% compared to Oxford Biomedica's net margin of -23.23%. PureTech Health's return on equity of 0.14% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	7.53%	0.14%	-13.39%
Oxford Biomedica	-23.23%	-54.51%	-12.67%

In the previous week, PureTech Health had 2 more articles in the media than Oxford Biomedica. MarketBeat recorded 3 mentions for PureTech Health and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.00 beat PureTech Health's score of -0.12 indicating that Oxford Biomedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Oxford Biomedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PureTech Health has a beta of 0.771, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.092, indicating that its stock price is 9% more volatile than the broader market.

Summary

PureTech Health beats Oxford Biomedica on 8 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Silence Therapeutics?

PureTech Health (LON:PRTC) and Silence Therapeutics (LON:SLN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

In the previous week, PureTech Health had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 3 mentions for PureTech Health and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 beat PureTech Health's score of -0.12 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Neutral
Silence Therapeutics	Neutral

31.0% of PureTech Health shares are owned by institutional investors. 13.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Silence Therapeutics has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£6.37M	42.76	-£91.86M	N/A	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

PureTech Health has a net margin of 7.53% compared to Silence Therapeutics' net margin of 0.00%. PureTech Health's return on equity of 0.14% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	7.53%	0.14%	-13.39%
Silence Therapeutics	N/A	N/A	N/A

PureTech Health presently has a consensus target price of GBX 508, suggesting a potential upside of 357.66%. Given PureTech Health's stronger consensus rating and higher probable upside, equities research analysts plainly believe PureTech Health is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

PureTech Health beats Silence Therapeutics on 9 of the 12 factors compared between the two stocks.

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

PureTech Health (LON:PRTC) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, PureTech Health had 3 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 3 mentions for PureTech Health and 0 mentions for Horizon Discovery Group plc (HZD.L). Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 beat PureTech Health's score of -0.12 indicating that Horizon Discovery Group plc (HZD.L) is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£6.37M	42.76	-£91.86M	N/A	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

PureTech Health has a net margin of 7.53% compared to Horizon Discovery Group plc (HZD.L)'s net margin of 0.00%. PureTech Health's return on equity of 0.14% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	7.53%	0.14%	-13.39%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

PureTech Health currently has a consensus price target of GBX 508, suggesting a potential upside of 357.66%. Given PureTech Health's stronger consensus rating and higher possible upside, equities analysts clearly believe PureTech Health is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

31.0% of PureTech Health shares are held by institutional investors. 13.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

PureTech Health beats Horizon Discovery Group plc (HZD.L) on 9 of the 12 factors compared between the two stocks.

How does PureTech Health compare to Avacta Group?

Avacta Group (LON:AVCT) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Avacta Group has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, indicating that its stock price is 23% less volatile than the broader market.

Avacta Group presently has a consensus price target of GBX 99, suggesting a potential upside of 51.15%. PureTech Health has a consensus price target of GBX 508, suggesting a potential upside of 357.66%. Given PureTech Health's higher probable upside, analysts clearly believe PureTech Health is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Avacta Group has higher earnings, but lower revenue than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,648.76	-£30.08M	-£9.24	N/A
PureTech Health	£6.37M	42.76	-£91.86M	N/A	N/A

In the previous week, Avacta Group had 1 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Avacta Group and 3 mentions for PureTech Health. Avacta Group's average media sentiment score of 0.00 beat PureTech Health's score of -0.12 indicating that Avacta Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

2.9% of Avacta Group shares are owned by institutional investors. Comparatively, 31.0% of PureTech Health shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by insiders. Comparatively, 13.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

PureTech Health has a net margin of 7.53% compared to Avacta Group's net margin of -35,730.97%. PureTech Health's return on equity of 0.14% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-35,730.97%	-1,293.07%	-21.80%
PureTech Health	7.53%	0.14%	-13.39%

Summary

PureTech Health beats Avacta Group on 7 of the 13 factors compared between the two stocks.

How does PureTech Health compare to Arix Bioscience?

PureTech Health (LON:PRTC) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, PureTech Health had 3 more articles in the media than Arix Bioscience. MarketBeat recorded 3 mentions for PureTech Health and 0 mentions for Arix Bioscience. Arix Bioscience's average media sentiment score of 0.00 beat PureTech Health's score of -0.12 indicating that Arix Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
PureTech Health	Neutral
Arix Bioscience	Neutral

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 357.66%. Given PureTech Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe PureTech Health is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Arix Bioscience has a net margin of 105.64% compared to PureTech Health's net margin of 7.53%. Arix Bioscience's return on equity of 6.41% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	7.53%	0.14%	-13.39%
Arix Bioscience	105.64%	6.41%	2.18%

PureTech Health has a beta of 0.771, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Arix Bioscience has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£6.37M	42.76	-£91.86M	N/A	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

31.0% of PureTech Health shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 13.3% of PureTech Health shares are owned by insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Arix Bioscience beats PureTech Health on 10 of the 14 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£274.60M	£3.93B	£7.25B	£2.81B
Dividend Yield	N/A	3.65%	2.53%	6.27%
P/E Ratio	-2.34	13.93	275.68	367.18
Price / Sales	43.14	1,171.06	579.26	88,394.79
Price / Cash	2.14	39.46	27.30	27.87
Price / Book	0.99	17.25	10.81	7.13
Net Income	-£91.86M	-£22.69M	£3.50B	£5.89B
7 Day Performance	4.09%	-2.33%	-1.59%	0.22%
1 Month Performance	-6.20%	-8.52%	-4.38%	-0.32%
1 Year Performance	-14.87%	13.91%	6.48%	22.91%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	2.2037 of 5 stars	GBX 112 +0.9%	GBX 508 +353.6%	-15.6%	£274.60M	£6.37M	N/A	300	Gap Up High Trading Volume
OXB Oxford Biomedica	1.9446 of 5 stars	GBX 521 +1.6%	GBX 613.32 +17.7%	-19.0%	£621.01M	£175.36M	N/A	891
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
AVCT Avacta Group	1.5817 of 5 stars	GBX 65.50 +2.3%	GBX 99 +51.1%	-7.0%	£299.31M	£113K	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:PRTC) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. OXB, SLN, HZD, AVCT, and ARIX

How does PureTech Health compare to Oxford Biomedica?

Summary

How does PureTech Health compare to Silence Therapeutics?

Summary

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does PureTech Health compare to Avacta Group?

Summary

How does PureTech Health compare to Arix Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. OXB, SLN, HZD, AVCT, and ARIX

How does PureTech Health compare to Oxford Biomedica?

Do analysts recommend PRTC or OXB?

Do institutionals & insiders hold more shares of PRTC or OXB?

Which has higher earnings & valuation, PRTC or OXB?

Is PRTC or OXB more profitable?

Does the media favor PRTC or OXB?

Which has more risk and volatility, PRTC or OXB?

Summary

How does PureTech Health compare to Silence Therapeutics?

Does the media prefer PRTC or SLN?

Do insiders & institutionals hold more shares of PRTC or SLN?

Which has stronger valuation & earnings, PRTC or SLN?

Is PRTC or SLN more profitable?

Do analysts rate PRTC or SLN?

Summary

How does PureTech Health compare to Horizon Discovery Group plc (HZD.L)?

Does the media favor PRTC or HZD?

Which has preferable valuation and earnings, PRTC or HZD?

Is PRTC or HZD more profitable?

Do analysts rate PRTC or HZD?

Do institutionals and insiders have more ownership in PRTC or HZD?

Summary

How does PureTech Health compare to Avacta Group?

Which has more volatility & risk, AVCT or PRTC?

Do analysts recommend AVCT or PRTC?

Which has stronger earnings & valuation, AVCT or PRTC?

Does the media refer more to AVCT or PRTC?

Do institutionals and insiders hold more shares of AVCT or PRTC?

Is AVCT or PRTC more profitable?

Summary

How does PureTech Health compare to Arix Bioscience?

Does the media refer more to PRTC or ARIX?

Do analysts rate PRTC or ARIX?

Is PRTC or ARIX more profitable?

Which has more volatility and risk, PRTC or ARIX?

Which has preferable earnings and valuation, PRTC or ARIX?

Do insiders and institutionals have more ownership in PRTC or ARIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools